Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
10
pubmed:dateCreated
2006-12-18
pubmed:abstractText
This study compared early postoperative complications in kidney transplant recipients treated with either a sirolimus-based calcineurin inhibitor (CNI)-free regimen or a tacrolimus-based steroid-free regimen. We used a single-center, prospective, sequential but nonrandomized study design. Consecutive recipients of primary cadaveric or non-HLA identical kidney transplant recipients received either a CNI-free regimen, consisting of sirolimus 5 mg daily beginning postoperative day 3, mycophenolate mofetil 1 gm twice a day, and methylprednisolone 500 mg intraoperatively, then prednisone 30 mg daily tapered to 10 mg daily at 3 months, or a prednisone-free regimen, consisting of methylprednisolone 500 mg, 250 mg, and 125 mg from days 0 to 2, then no further steroids, tacrolimus 0.075 mg/kg twice a day, and mycophenolate mofetil 1 g twice a day. All patients received thymoglobulin induction 6 mg/kg total dose. Outcome measures were patient and graft survival, BPAR, surgical and wound complications, viral infections and posttransplant diabetes mellitus (PTDM). Both groups had excellent early outcomes with no significant difference in patient or graft survival, early renal function, BPAR, surgical or wound complications, or viral infections between the two groups. Patients in the sirolimus-based CNI-free group had a significantly higher incidence of PTDM and a trend toward more discontinuation due to drug toxicity. Whether either regimen improves long-term outcomes awaits longer follow-up.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0041-1345
pubmed:author
pubmed:issnType
Print
pubmed:volume
38
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
3464-5
pubmed:dateRevised
2008-11-21
pubmed:meshHeading
pubmed-meshheading:17175304-Adrenal Cortex Hormones, pubmed-meshheading:17175304-Adult, pubmed-meshheading:17175304-Cadaver, pubmed-meshheading:17175304-Calcineurin, pubmed-meshheading:17175304-Continental Population Groups, pubmed-meshheading:17175304-Drug Therapy, Combination, pubmed-meshheading:17175304-Female, pubmed-meshheading:17175304-Graft Survival, pubmed-meshheading:17175304-Histocompatibility Testing, pubmed-meshheading:17175304-Humans, pubmed-meshheading:17175304-Kidney Transplantation, pubmed-meshheading:17175304-Male, pubmed-meshheading:17175304-Middle Aged, pubmed-meshheading:17175304-Mycophenolic Acid, pubmed-meshheading:17175304-Patient Selection, pubmed-meshheading:17175304-Postoperative Complications, pubmed-meshheading:17175304-Survival Analysis, pubmed-meshheading:17175304-Tacrolimus, pubmed-meshheading:17175304-Tissue Donors, pubmed-meshheading:17175304-Treatment Outcome
pubmed:year
2006
pubmed:articleTitle
Calcineurin inhibitor avoidance versus steroid avoidance following kidney transplantation: Postoperative complications.
pubmed:affiliation
Division of Kidney and Pancreas Transplantation, Vanderbilt University Medical Center, Nashville, Tennessee 37232-4750, USA.
pubmed:publicationType
Journal Article, Controlled Clinical Trial